444 related articles for article (PubMed ID: 37163445)
1. Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.
Huang EJ; Wu MH; Wang TJ; Huang TJ; Li YR; Lee CY
Aging Dis; 2023 Aug; 14(4):1070-1092. PubMed ID: 37163445
[TBL] [Abstract][Full Text] [Related]
2. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
[TBL] [Abstract][Full Text] [Related]
3. [Myasthenia gravis: current status of antibody diagnostics and aspects on refractory myasthenia gravis].
Wenninger S; Schoser B
Fortschr Neurol Psychiatr; 2018 Sep; 86(9):551-558. PubMed ID: 30248688
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
Lazaridis K; Tzartos SJ
Front Immunol; 2020; 11():212. PubMed ID: 32117321
[TBL] [Abstract][Full Text] [Related]
5. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
Ohta R; Motomura M
Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.
Mané-Damas M; Molenaar PC; Ulrichts P; Marcuse F; De Baets MH; Martinez-Martinez P; Losen M
Autoimmun Rev; 2022 Jul; 21(7):103104. PubMed ID: 35452851
[TBL] [Abstract][Full Text] [Related]
7. Myasthenia gravis: subgroup classification and therapeutic strategies.
Gilhus NE; Verschuuren JJ
Lancet Neurol; 2015 Oct; 14(10):1023-36. PubMed ID: 26376969
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.
Lazaridis K; Tzartos SJ
Front Neurol; 2020; 11():596981. PubMed ID: 33329350
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
Phillips WD; Vincent A
F1000Res; 2016; 5():. PubMed ID: 27408701
[TBL] [Abstract][Full Text] [Related]
10. Double-seropositive myasthenia gravis with acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma.
Ishikawa H; Taniguchi A; Ii Y; Higuchi O; Matsuo H; Nakane S; Asahi M; Niwa A; Tomimoto H
Neuromuscul Disord; 2017 Oct; 27(10):914-917. PubMed ID: 28694075
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
Shen C; Lu Y; Zhang B; Figueiredo D; Bean J; Jung J; Wu H; Barik A; Yin DM; Xiong WC; Mei L
J Clin Invest; 2013 Dec; 123(12):5190-202. PubMed ID: 24200689
[TBL] [Abstract][Full Text] [Related]
12. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.
De Rosa A; Fornili M; Maestri Tassoni M; Guida M; Baglietto L; Petrucci L; Chella A; Melfi F; Lucchi M; Ricciardi R
Thorac Cancer; 2021 Jan; 12(1):106-113. PubMed ID: 33142021
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis with anti-acetylcholine receptor antibodies.
Meriggioli MN
Front Neurol Neurosci; 2009; 26():94-108. PubMed ID: 19349707
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and clinical classification of autoimmune myasthenia gravis.
Berrih-Aknin S; Frenkian-Cuvelier M; Eymard B
J Autoimmun; 2014; 48-49():143-8. PubMed ID: 24530233
[TBL] [Abstract][Full Text] [Related]
15. Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis.
Li M; Han J; Zhang Y; Lv J; Zhang J; Zhao X; Ren L; Fang H; Yang J; Zhang Y; Cui X; Zhang Q; Li Q; Du Y; Gao F
Eur J Neurol; 2019 Oct; 26(10):1296-e84. PubMed ID: 31050101
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia and the neuromuscular junction.
Gilhus NE
Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment.
Cao M; Koneczny I; Vincent A
Front Mol Neurosci; 2020; 13():159. PubMed ID: 32982689
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in myasthenia gravis: considerations for disease management.
Evoli A; Spagni G; Monte G; Damato V
Expert Rev Clin Immunol; 2021 Jul; 17(7):761-771. PubMed ID: 34043932
[No Abstract] [Full Text] [Related]
19. Seropositive Muscle-Specific Tyrosine Kinase Myasthenia Gravis Presenting as a Late-Onset Isolated Sixth Nerve Palsy: A Case Report and a Brief Review of Subtypes of Myasthenia Gravis.
Park G; Kesserwani H
Cureus; 2021 Nov; 13(11):e19701. PubMed ID: 34934570
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
